Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D. Cohen; Luciano J. Costa; Madhav V. Dhodapkar; Francesca Gay; Nicole Gormley; Damian J. Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C. Pasquini; Noemi Puig; G. David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A. Shah; Qian Shi; Andrew Spencer; Vera J. Suman; Saad Z. Usmani; Philip L. McCarthy

doi:10.1016/j.bbmt.2020.06.011

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein, Alan Howard, David Avigan, Manisha Bhutani, Adam D. Cohen, Luciano J. Costa, Madhav V. Dhodapkar, Francesca Gay, Nicole Gormley, Damian J. Green, Jens Hillengass, Neha Korde, Zihai Li, Sham Mailankody, Paola Neri, Samir Parekh, Marcelo C. Pasquini, Noemi Puig, G. David Roodman, Mehmet Kemal SamurNina Shah, Urvi A. Shah, Qian Shi, Andrew Spencer, Vera J. Suman, Saad Z. Usmani, Philip L. McCarthy

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

Original language	English
Pages (from-to)	e247-e255
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	10
DOIs	https://doi.org/10.1016/j.bbmt.2020.06.011
State	Published - Oct 2020

Keywords

CAR T cell
Endpoint
Immune profiling
Minimal residual disease
Multiple myeloma

Access to Document

10.1016/j.bbmt.2020.06.011

Cite this

Holstein, S. A., Howard, A., Avigan, D., Bhutani, M., Cohen, A. D., Costa, L. J., Dhodapkar, M. V., Gay, F., Gormley, N., Green, D. J., Hillengass, J., Korde, N., Li, Z., Mailankody, S., Neri, P., Parekh, S., Pasquini, M. C., Puig, N., Roodman, G. D., ... McCarthy, P. L. (2020). Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 26(10), e247-e255. https://doi.org/10.1016/j.bbmt.2020.06.011

@article{215dce03a29d4325b8700cc23fa11cfb,

title = "Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",

abstract = "The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.",

keywords = "CAR T cell, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",

author = "Holstein, {Sarah A.} and Alan Howard and David Avigan and Manisha Bhutani and Cohen, {Adam D.} and Costa, {Luciano J.} and Dhodapkar, {Madhav V.} and Francesca Gay and Nicole Gormley and Green, {Damian J.} and Jens Hillengass and Neha Korde and Zihai Li and Sham Mailankody and Paola Neri and Samir Parekh and Pasquini, {Marcelo C.} and Noemi Puig and Roodman, {G. David} and Samur, {Mehmet Kemal} and Nina Shah and Shah, {Urvi A.} and Qian Shi and Andrew Spencer and Suman, {Vera J.} and Usmani, {Saad Z.} and McCarthy, {Philip L.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = oct,

doi = "10.1016/j.bbmt.2020.06.011",

language = "English",

volume = "26",

pages = "e247--e255",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier B.V.",

number = "10",

}

Holstein, SA, Howard, A, Avigan, D, Bhutani, M, Cohen, AD, Costa, LJ, Dhodapkar, MV, Gay, F, Gormley, N, Green, DJ, Hillengass, J, Korde, N, Li, Z, Mailankody, S, Neri, P, Parekh, S, Pasquini, MC, Puig, N, Roodman, GD, Samur, MK, Shah, N, Shah, UA, Shi, Q, Spencer, A, Suman, VJ, Usmani, SZ & McCarthy, PL 2020, 'Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling', Biology of Blood and Marrow Transplantation, vol. 26, no. 10, pp. e247-e255. https://doi.org/10.1016/j.bbmt.2020.06.011

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. / Holstein, Sarah A.; Howard, Alan; Avigan, David et al.
In: Biology of Blood and Marrow Transplantation, Vol. 26, No. 10, 10.2020, p. e247-e255.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

AU - Holstein, Sarah A.

AU - Howard, Alan

AU - Avigan, David

AU - Bhutani, Manisha

AU - Cohen, Adam D.

AU - Costa, Luciano J.

AU - Dhodapkar, Madhav V.

AU - Gay, Francesca

AU - Gormley, Nicole

AU - Green, Damian J.

AU - Hillengass, Jens

AU - Korde, Neha

AU - Li, Zihai

AU - Mailankody, Sham

AU - Neri, Paola

AU - Parekh, Samir

AU - Pasquini, Marcelo C.

AU - Puig, Noemi

AU - Roodman, G. David

AU - Samur, Mehmet Kemal

AU - Shah, Nina

AU - Shah, Urvi A.

AU - Shi, Qian

AU - Spencer, Andrew

AU - Suman, Vera J.

AU - Usmani, Saad Z.

AU - McCarthy, Philip L.

PY - 2020/10

Y1 - 2020/10

N2 - The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

AB - The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

KW - CAR T cell

KW - Endpoint

KW - Immune profiling

KW - Minimal residual disease

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85087955631&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.06.011

DO - 10.1016/j.bbmt.2020.06.011

M3 - Review article

C2 - 32589921

AN - SCOPUS:85087955631

SN - 1083-8791

VL - 26

SP - e247-e255

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 10

ER -

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Abstract

Keywords

Access to Document

Fingerprint

Cite this